Evaluating the long-term benefits of hydroxyurea in pediatric sickle cell anemia
Abstract: Hydroxyurea is the primary disease-modifying medication for sickle cell anemia (SCA), but its long-term effects, particularly how these effects change over time, are not well understood. This study aimed to quantify the effects of hydroxyurea on clinical and laboratory outcomes in children...
Uloženo v:
| Hlavní autoři: | , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Elsevier
2025-07-01
|
| Edice: | Blood Advances |
| On-line přístup: | http://www.sciencedirect.com/science/article/pii/S247395292500237X |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|